Driving Progress in Biotech Research

We are Developing a New Generation of Precision-Delivered RNA Therapeutics with Life-Saving Potential

Two Pillars of Precision Technology

GalNAc-siRNA1: potential to treat liver failure and fatty liver in metabolic syndrome

  • Potent preclinical activity, while targeted delivery limits side-effects
  • Development prioritizes significant unmet need in primary liver cancer patients with liver failure, orphan indication

Transferrin aptamer1,2: potential to deliver therapeutics to the brain

  • Unique platform with extensive licensing potential across payload and indication
  • Payload identified with potentially potent activity in brain metastases in triple negative breast cancer (TNBC) patients

Investment Opportunity with Clear Catalysts for Value Creation

  • £26M phased in two tranches to fund Phase 1b and pivotal Phase 2a in liver failure, and to strengthen preclinical data for unique aptamer delivery platform

1 Proprietary payload information for each program available under CDA
2 Exclusively licensed from City of Hope